A Randomized, Blinded, Positively Controlled Phase I Clinical Trial to Evaluate the Safety and Initial Immunogenicity of Trivalent Influenza Vaccine (Split Virion),Inactivated (MDCK Cell) Vaccination in a Population 6 Months of Age and Older

Start Date10 Feb 2025

Sponsor / Collaborator

Guangdong Disease Prevention & Control Center

ChiCTR2400094382

/ RecruitingNot ApplicableIIT

Research and Transformation of Lingnan Dietary Patterns

Start Date12 Dec 2024

Sponsor / Collaborator

Guangdong Disease Prevention & Control Center

NCT01305694

/ Unknown statusPhase 1/2IIT

PhaseⅠ/ⅡTrial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia.

The study is a phase I/II trial designed to establish the safety and efficacy of intravenous administration of bone marrow derived mesenchymal stem cells from related donor to patients with relapsed/refractory aplastic anemia.

Start Date01 Feb 2011

Sponsor / Collaborator

Guangdong Disease Prevention & Control Center

[+1]

100 Clinical Results associated with Guangdong Disease Prevention & Control Center

0 Patents (Medical) associated with Guangdong Disease Prevention & Control Center

402

Literatures (Medical) associated with Guangdong Disease Prevention & Control Center

31 Dec 2025·Expert Review of Vaccines

The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China

Article

Author: Xiao, Jianpeng ; Li, Jialing ; Fan, Zhongyi ; Zeng, Siqing ; Hu, Pei ; Li, Zhihao ; He, Jianfeng ; Zhu, Zhihua ; Huang, Xing ; Liu, Jun ; Sun, Limei ; Yang, Ying ; Zhu, Qi ; Zeng, Weilin ; Li, Yihan

BACKGROUNDChina implemented diverse varicella vaccination strategies from 2012 to 2022, with unclear protective effects. The study aimed to evaluate the effects of two varicella vaccination (VarV) (the two-dose self-paid VarV and the two-dose free VarV) strategies implemented in Guangdong Province, China.RESEARCH DESIGN AND METHODSWe collected data on varicella cases and doses administered to children aged 0-14 in Guangzhou, Shenzhen, and Foshan from 2012 to 2022. Using Bayesian Structured Time Series (BSTS) model, we estimated the effects of the two VarV strategies in Guangzhou and Shenzhen starting from 2018, by referencing Foshan.RESULTSPost-implementation of the two-dose self-paid VarV strategy 36,749 (95% CI: 29070, 44428) and 24,179 (95% CI: 16400, 31958) varicella cases were averted in Guangzhou and Shenzhen, with a protection rate of 41.8% (95% CI: 36.3%, 46.5%) and 38.9% (95% CI: 30.2%, 45.7%), respectively. After the adoption of the two-dose free VarV strategy, a substantial relative protection rate of 64.2% (95% CI: 58.0%, 68.7%) in varicella cases was observed in Shenzhen, with 38,828 (95% CI: 29979, 47677) cases averted by 2022.CONCLUSIONSThe two-dose VarV strategies have proven highly effective in reducing varicella incidence. The experience in Shenzhen underscores the benefits of a two-dose free VarV strategy.

01 Aug 2025·Environmental Research

Associations of long-term exposure to PM2.5 and its constituents with children renal function: a national retrospective study in China

Article

Author: Dong, Xiaomei ; Yang, Shangfeng ; Ma, Wenjun ; Liu, Dan ; Yu, Siwen ; Wu, Wei ; Zhu, Qijiong ; Liu, Tao ; He, Guanhao ; Hu, Jianxiong ; Sun, Xiaoli ; Peng, Jiewen ; Chen, Zhiqing ; Cui, Chunxia ; Liu, Yiya ; Yu, Lianlong ; Lin, Yi

INTRODUCTIONAmbient fine particulate matter with aerodynamic diameter ≤2.5 μm (PM_2.5) harms adult's renal health. However, research on the associations of PM_2.5 and its chemical constituents (black carbon (BC), ammonium (), nitrate (), organic matter (OM), and sulfate ()) with children' kidney health is lacking.OBJECTIVESThe aim of this research was to estimate the associations between long-term exposures to PM_2.5 and its constituents and children' estimated glomerular filtration rate (eGFR).METHODSWe investigated 9770 children from 5 provinces across China during 2016-2017. The eGFR was calculated from serum creatinine. We estimated the mean concentration of PM_2.5 and PM_2.5 compositions (BC, , , OM, ) during pregnancy, infancy and preschool period for each subject. A generalized linear mixed-effects model was utilized to estimate associations of PM_2.5 and its constituents with eGFR. Stratified analyses were conducted to explore effect modifications of sex and urbanicity.RESULTSDuring the full pregnancy, each interquartile range (IQR) increase in PM_2.5 mass (49.07 μg/m³), (9.14 μg/m³), BC (1.85 μg/m³), (7.38 μg/m³), (12.23 μg/m³) and OM (9.02 μg/m³) was associated with decreased eGFR (ml/min/1.73 m²), with changes of -1.80 (95% CI: -2.82, -0.78), -1.70 (95% CI: -2.71, -0.69), -1.83 (95% CI: -2.63, -1.03), -6.87 (95% CI: -8.44, -5.30), -7.24 (95% CI: -9.02, -5.45), and -2.20 (95% CI: -3.12, -1.28), respectively. In infancy, higher levels of BC, , , and OM were negatively associated with eGFR, and similar associations were found during the preschool period for , , and OM. Furthermore, children living in rural areas were particularly sensitive to PM_2.5.CONCLUSIONLong-term exposures to PM_2.5 and some constituents were negatively associated with children's eGFR. Additionally, the associations of and constituents were more pronounced with renal health than the other chemical constituents. Targeted policies are needed to protect kidney health from PM_2.5 exposure.

01 May 2025·International Journal of Infectious Diseases

Global containment policy duration and long-term epidemic progression: A target trial emulation using COVID-19 data from 2020 to 2022

Article

Author: Wu, Kunpeng ; Xiong, Wenxue ; Wang, Wenjuan ; Ling, Li ; Chen, Wen ; He, Qun ; Chen, Senke ; Zheng, Meng ; Wang, Xin ; Li, Zhiyao ; Wang, Zhen ; Fan, Chaonan

OBJECTIVESGlobal countries often apply containment policies (CPs) to combat infectious disease surges. Whether countries with longer cumulative duration of CPs are associated with slower long-term epidemic progression necessitates a thorough evaluation.METHODSWe collected CP and COVID-19 data of 185 territories during 2020-2022, with a total of 23 CPs. Using the target trial emulation and cloning-censoring-weighting approaches, we assessed the effectiveness of CPs with different cumulative durations in delaying countries from reaching the 1% and 10% cumulative infection incidence end points (i.e. 10,000 and 100,000 COVID-19 cases per million population, respectively) over a 3-year observation period.RESULTSFor reaching the 1% cumulative infection incidence, recommending closing workplaces and limiting gatherings to 10 people, each presented that a longer cumulative duration of those CPs is associated with a lower proportion of countries achieving this end point throughout 2020-2022. For reaching the 10% cumulative infection incidence, mandatory bans on public events and domestic movements, closing public transports, and screening and quarantining inbound tourists, each showed similar associations. Notably, long-lasting border bans upon high-risk regions are associated with a higher proportion of countries reaching the 10% cumulative infection incidence.CONCLUSIONSFrom the long-term perspective, we highlight CPs that warrant extending the duration to achieve slower epidemic progression. By contrast, our findings demonstrate the limited effectiveness of the ban on regions in slowing the long-term epidemic progression.

100 Deals associated with Guangdong Disease Prevention & Control Center

100 Translational Medicine associated with Guangdong Disease Prevention & Control Center

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 28 Feb 2026

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis